APGE
NASDAQApogee Therapeutics Inc.
Price$135.08+55.77 (+70.31%)
2026-06-012026-09-02
News · 26 weeks76-100%
2026-04-192026-10-11
Mix3090d
- Insider12(40%)
- SEC Filings11(37%)
- Other7(23%)
Latest news
25 items- SECSEC Form 15-12G filed by Apogee Therapeutics Inc.15-12G - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Apogee Therapeutics Inc.SCHEDULE 13D/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Apogee Therapeutics Inc.SCHEDULE 13D/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- INSIDERDirector Fairmount Funds Management Llc returned 443,187 shares to the company (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERDirector Jones William A Jr returned 34,824 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERChief Financial Officer Henderson Jane returned 158,371 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Apogee Therapeutics Inc.4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Apogee Therapeutics Inc.4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Apogee Therapeutics Inc.4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Apogee Therapeutics Inc.4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERChief Medical Officer Dambkowski Carl returned $185,708 worth of shares to the company (168,498 units at $1.10), closing all direct ownership in the company (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERChief Executive Officer Henderson Michael Thomas returned 920,941 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECSEC Form POSASR filed by Apogee Therapeutics Inc.POSASR - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form S-8 POS filed by Apogee Therapeutics Inc.S-8 POS - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form S-8 POS filed by Apogee Therapeutics Inc.S-8 POS - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form S-8 POS filed by Apogee Therapeutics Inc.S-8 POS - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form S-8 POS filed by Apogee Therapeutics Inc.S-8 POS - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form S-8 POS filed by Apogee Therapeutics Inc.S-8 POS - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form 25-NSE filed by Apogee Therapeutics Inc.25-NSE - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- PRAbbVie Completes Acquisition of Apogee TherapeuticsAcquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseasesApogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitisApogee's pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthmaAbbVie reaffirms previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88NORTH
- INSIDERDirector Fairmount Funds Management Llc exercised 42,208 shares at a strike of $23.60 (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form 10-Q filed by Apogee Therapeutics Inc.10-Q - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
APGE FAQ
6 questionsWhere does APGE stock trade?
Apogee Therapeutics Inc. (APGE) is listed on NASDAQ.What sector and industry is APGE in?
Apogee Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Apogee Therapeutics Inc. go public?
Apogee Therapeutics Inc. (APGE) completed its IPO in 2023.What are analysts saying about APGE?
Apogee Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Rothschild & Co Redburn: Buy on 2026-05-01.What companies are similar to APGE?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare APGE side-by-side with any of them on Quantisnow.How can I track APGE on Quantisnow?
Quantisnow aggregates Apogee Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APGE to receive live email and push alerts on every new disclosure.